Inovio Pharmaceuticals (NASDAQ:INO) will post its quarterly earnings results after the market closes on Thursday, November 8th. Analysts expect Inovio Pharmaceuticals to post earnings of ($0.32) per share for the quarter.
Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.27. The business had revenue of $24.45 million for the quarter, compared to analysts’ expectations of $2.13 million. Inovio Pharmaceuticals had a negative return on equity of 71.53% and a negative net margin of 252.95%. On average, analysts expect Inovio Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of Inovio Pharmaceuticals stock opened at $4.93 on Thursday. The company has a market capitalization of $461.14 million, a price-to-earnings ratio of -4.55 and a beta of 1.74. Inovio Pharmaceuticals has a one year low of $3.64 and a one year high of $6.30.
In other news, CEO Jong Joseph Kim sold 49,060 shares of Inovio Pharmaceuticals stock in a transaction that occurred on Wednesday, September 12th. The stock was sold at an average price of $5.37, for a total value of $263,452.20. Following the sale, the chief executive officer now directly owns 2,357,554 shares in the company, valued at approximately $12,660,064.98. The sale was disclosed in a filing with the SEC, which is available through this link. 9.40% of the stock is currently owned by company insiders.
A number of equities analysts have commented on the company. BidaskClub cut Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, October 26th. HC Wainwright set a $13.00 price objective on Inovio Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, October 23rd. Stifel Nicolaus started coverage on Inovio Pharmaceuticals in a research report on Tuesday, October 2nd. They issued a “buy” rating and a $8.00 price objective on the stock. Finally, ValuEngine upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, September 5th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $10.75.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
Featured Story: How to Calculate Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.